Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Comparing Custom Targeted DNA Sequencing Panel vs FISH for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
Long-Term Results of Acalabrutinib-Based Regimens in CLL
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Quiz
Adding Venetoclax to High-Risk Chronic Lymphocytic Leukemia Treatment
10/31/2023
The addition of venetoclax therapy among patients with high-risk chronic lymphocytic leukemia who had received at least ___ months or more of ibrutinib treatment achieved a high rate of undetectable measurable residual disease (U-MRD) in the...
The addition of venetoclax therapy among patients with high-risk chronic lymphocytic leukemia who had received at least ___ months or more of ibrutinib treatment achieved a high rate of undetectable measurable residual disease (U-MRD) in the...
The addition of venetoclax...
10/31/2023
Oncology
Quiz
Venetoclax for CLL With High-Risk Features
10/05/2023
The addition of venetoclax therapy yielded high rates of undetectable measurable residual disease (U-MRD) in the bone marrow among patients with CLL who had received ibrutinib for ≥12 months and had high-risk features, including ___.
The addition of venetoclax therapy yielded high rates of undetectable measurable residual disease (U-MRD) in the bone marrow among patients with CLL who had received ibrutinib for ≥12 months and had high-risk features, including ___.
The addition of venetoclax...
10/05/2023
Oncology
Quiz
Ibrutinib Plus Venetoclax Combination for Previously Untreated CLL
09/01/2023
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the...
09/01/2023
Oncology
Quiz
FDA Approval of Zanubrutinib for CLL/SLL
05/23/2023
The FDA approved zanubrutinib for CLL or SLL based on efficacy results from the ALPINE trial, which indicated that the overall response rate among patients who received this treatment was ____.
The FDA approved zanubrutinib for CLL or SLL based on efficacy results from the ALPINE trial, which indicated that the overall response rate among patients who received this treatment was ____.
The FDA approved zanubrutinib...
05/23/2023
Oncology
Quiz
Quiz: Overall Survival Rate of Venetoclax Plus Rituximab Treatment in Patients With Relapsed/Refractory CLL
12/01/2022
What was the overall survival rate of venetoclax plus rituximab treatment in patients with relapsed/refractory CLL at 3 years following cessation, according to a 5-year update of a phase 3 trial? 
What was the overall survival rate of venetoclax plus rituximab treatment in patients with relapsed/refractory CLL at 3 years following cessation, according to a 5-year update of a phase 3 trial? 
What was the overall survival...
12/01/2022
Oncology
Quiz
Quiz: Obinutuzumab in Patients With Chronic Lymphocytic Leukemia That Responded to Chemo-Immunotherapy
12/01/2022
True or false: Obinutuzumab is well-tolerated in patients with chronic lymphocytic leukemia that responded to chemo-immunotherapy, according to a phase 2/3 trial.
True or false: Obinutuzumab is well-tolerated in patients with chronic lymphocytic leukemia that responded to chemo-immunotherapy, according to a phase 2/3 trial.
True or false: Obinutuzumab is...
12/01/2022
Oncology
Quiz
Quiz: Zanubrutinib as Frontline Therapy for CLL and SLL
10/12/2022
True or False: Zanubrutinib significantly improved progression-free survival vs bendamustine–rituximab as a frontline therapy for CLL and SLL.
True or False: Zanubrutinib significantly improved progression-free survival vs bendamustine–rituximab as a frontline therapy for CLL and SLL.
True or False: Zanubrutinib...
10/12/2022
Oncology
Quiz
Quiz: MRD-Guided, Time-Limited Treatment With Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL
09/05/2022
True or false: MRD-guided, time-limited treatment with ibrutinib plus venetoclax may be beneficial for patients with relapsed/refractory CLL, according to a phase 2 trial.
True or false: MRD-guided, time-limited treatment with ibrutinib plus venetoclax may be beneficial for patients with relapsed/refractory CLL, according to a phase 2 trial.
True or false: MRD-guided,...
09/05/2022
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use